Literature DB >> 30922920

Long noncoding RNA CCAT2 promotes hepatocellular carcinoma proliferation and metastasis through up-regulation of NDRG1.

Yuyang Liu1, Dan Wang2, Yongguo Li3, Shaoying Yan4, Hao Dang5, Huan Yue6, Jiaji Ling7, Fengjiao Chen8, Yannan Zhao9, Luxia Gou10, Ping Tang11, Ailong Huang12, Hua Tang13.   

Abstract

BACKGROUND: Emerging studies demonstrate that long noncoding RNAs (lncRNAs) play crucial roles in hepatocarcinogenesis through various mechanisms. LncRNA CCAT2 was a newly discovered lncRNA and amplified in several cancers. However, the mechanisms involved in function of CCAT2 in hepatocellular carcinoma (HCC) remain to be explored.
METHODS: CCAT2 expressions in HCC tissues and cell lines were measured by RT-qPCR. MTS assay, colony formation assay, wound-healing assay and transwell assay were used to explore the biological functions of CCAT2 on HCC cells proliferation and metastasis. Experiments in vivo were carried out to confirm these effects. The underlying mechanisms were analyzed by western blot and dual-luciferase reporter assay.
RESULTS: In this study, we found that CCAT2 were significantly elevated in HCC tissues and cell lines, and it promoted HCC cells proliferation and metastasis both in vitro and in vivo. Additionally, we identified that NDRG1 was a downstream target of CCAT2. Meanwhile, depletion of CCAT2 inhibited cellular proliferation and metastasis behaviors induced by NDRG1- overexpression. Analysis of mechanism underlying these effects revealed that CCAT2 increased the expression of NDRG1 by enhancing its promoter activity. Furthermore, the active region between CCAT2 and NDRG1 promoter was confirmed by dual-luciferase reporter assay.
CONCLUSIONS: All these observations demonstrate that CCAT2 acts as an oncogene by up-regulating NDRG1, which may have the potential to be used as a promising prognostic biomarker and therapeutic target for HCC.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CCAT2; HCC; Metastasis; NDRG1; Proliferation

Mesh:

Substances:

Year:  2019        PMID: 30922920     DOI: 10.1016/j.yexcr.2019.03.029

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  15 in total

1.  Machine Learning Screens Potential Drugs Targeting a Prognostic Gene Signature Associated With Proliferation in Hepatocellular Carcinoma.

Authors:  Jun Liu; Jianjun Lu; Wenli Li; Wenjie Mao; Yamin Lu
Journal:  Front Genet       Date:  2022-06-28       Impact factor: 4.772

2.  NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis.

Authors:  Emilly S Villodre; Xiaoding Hu; Bedrich L Eckhardt; Richard Larson; Lei Huo; Ester C Yoon; Yun Gong; Juhee Song; Shuying Liu; Naoto T Ueno; Savitri Krishnamurthy; Stefan Pusch; Debu Tripathy; Wendy A Woodward; Bisrat G Debeb
Journal:  J Natl Cancer Inst       Date:  2022-04-11       Impact factor: 11.816

3.  Association of lncRNA CCAT2 and CASC8 Gene Polymorphisms with Hepatocellular Carcinoma.

Authors:  Edie-Rosmin Wu; Ming-Ju Hsieh; Whei-Ling Chiang; Kuan-Chun Hsueh; Shun-Fa Yang; Shih-Chi Su
Journal:  Int J Environ Res Public Health       Date:  2019-08-08       Impact factor: 3.390

Review 4.  Long Non-coding RNAs in Myeloid Malignancies.

Authors:  Alina-Andreea Zimta; Ciprian Tomuleasa; Iman Sahnoune; George A Calin; Ioana Berindan-Neagoe
Journal:  Front Oncol       Date:  2019-10-18       Impact factor: 6.244

5.  A Comprehensive Exploration of the lncRNA CCAT2: A Pan-Cancer Analysis Based on 33 Cancer Types and 13285 Cases.

Authors:  Bowen Huang; Min Yu; Renguo Guan; Dong Liu; Baohua Hou
Journal:  Dis Markers       Date:  2020-02-24       Impact factor: 3.434

6.  LINC00844 promotes proliferation and migration of hepatocellular carcinoma by regulating NDRG1 expression.

Authors:  Wei Zhou; Kang Huang; Qiuyan Zhang; Shaojun Ye; Zibiao Zhong; Cheng Zeng; Guizhu Peng; Ling Li; Qifa Ye
Journal:  PeerJ       Date:  2020-01-28       Impact factor: 2.984

7.  Long non-coding RNA LINC01503 promotes the progression of hepatocellular carcinoma via activating MAPK/ERK pathway.

Authors:  Mu-Ru Wang; Dan Fang; Mu-Ping Di; Jia-Lun Guan; Ge Wang; Lian Liu; Jia-Qi Sheng; De-An Tian; Pei-Yuan Li
Journal:  Int J Med Sci       Date:  2020-05-18       Impact factor: 3.738

8.  Increased expression of long non-coding RNA CCAT2 predicts poorer prognosis in patients with hepatocellular carcinoma.

Authors:  Changbo Fu; Xuan Xu; Weijun Lu; Lei Nie; Tao Yin; Dongde Wu
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

Review 9.  Long Non-Coding RNAs: Potential Biomarkers and Targets for Hepatocellular Carcinoma Therapy and Diagnosis.

Authors:  Donghong Yuan; Yu Chen; Xiaobing Li; Jing Li; Yueshui Zhao; Jing Shen; Fukuan Du; Parham Jabbarzadeh Kaboli; Mingxing Li; Xu Wu; Huijiao Ji; Chi Hin Cho; Qinglian Wen; Wanping Li; Zhangang Xiao; Bo Chen
Journal:  Int J Biol Sci       Date:  2021-01-01       Impact factor: 6.580

10.  Molecular Interplays Between Cell Invasion and Radioresistance That Lead to Poor Prognosis in Head-Neck Cancer.

Authors:  Guo-Rung You; Joseph T Chang; Yan-Liang Li; Yin-Ju Chen; Yu-Chen Huang; Kang-Hsing Fan; Yen-Chao Chen; Chung-Jan Kang; Ann-Joy Cheng
Journal:  Front Oncol       Date:  2021-07-09       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.